Kiyonobu Ueno
Overview
Explore the profile of Kiyonobu Ueno including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
91
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tanaka S, Yoshimura N, Asakawa R, Tobita S, Yaga M, Ueno K
Medicine (Baltimore)
. 2024 Jul;
103(30):e39094.
PMID: 39058830
Rationale: Extracorporeal membrane oxygenation (ECMO) is the last trump card for severe respiratory failure. The main complications of ECMO are bleeding and thrombosis, both of which can be life-threatening. Large...
2.
Matsumoto K, Yamamoto Y, Shiroyama T, Kuge T, Mori M, Tamiya M, et al.
Target Oncol
. 2024 Jul;
19(5):757-767.
PMID: 38990462
Background: Chemoimmunotherapy is a standard treatment for advanced non-small-cell lung cancer (NSCLC). However, data on clinical predictive factors remain scarce. Objective: We aim to identify clinical biomarkers in patients undergoing...
3.
Kanemura H, Yokoyama T, Nakajima R, Nakamura A, Kuroda H, Kitamura Y, et al.
JTO Clin Res Rep
. 2024 Apr;
5(4):100658.
PMID: 38651033
Introduction: Immune checkpoint inhibitors have recently been approved for the treatment of early-stage NSCLC in the perioperative setting on the basis of phase 3 trials. However, the characteristics of such...
4.
Matsumoto K, Shiroyama T, Tamiya M, Minami T, Kinehara Y, Tamiya A, et al.
Cancer Immunol Immunother
. 2024 Jan;
73(1):4.
PMID: 38175294
Introduction: Nivolumab plus ipilimumab with chemotherapy (NICT) and pembrolizumab with chemotherapy (PCT) are commonly used in patients with advanced non-small cell lung cancer (NSCLC). Compared with immune checkpoint inhibitor (ICI)...
5.
Tanaka S, Yoshimura N, Asakawa R, Tobita S, Yaga M, Ueno K
Thorac Cancer
. 2023 Jul;
14(25):2618-2621.
PMID: 37488715
Previously, cytotoxic drugs were the only option for patients with non-small cell lung cancer (NSCLC) and the prognosis was poor. However, molecularly targeted therapies and immune checkpoint inhibitors represent a...
6.
Tanizaki S, Matsumoto K, Tamiya A, Taniguchi Y, Matsuda Y, Uchida J, et al.
Eur J Clin Pharmacol
. 2023 Feb;
79(4):503-511.
PMID: 36773042
Objectives: Ramucirumab (RAM) and docetaxel (DOC) are commonly used after first-line therapy for advanced non-small cell lung cancer (NSCLC). Therefore, we aimed to elucidate sequencing strategies of RAM and DOC...
7.
Tanaka S, Takayama Y, Kitou R, Asakawa R, Tobita S, Ike A, et al.
Clin Case Rep
. 2022 Dec;
10(12):e6754.
PMID: 36567689
Coronavirus disease 2019 (COVID-19) has become a worldwide outbreak, and it can cause various symptoms and complications. However, pneumothorax secondary to COVID-19 is relatively uncommon. We herein report a 60-year-old...
8.
Tanaka S, Komuta K, Asakawa R, Tanizaki S, Kanai T, Uchida J, et al.
J Bronchology Interv Pulmonol
. 2022 Jun;
29(3):e31-e33.
PMID: 35730781
No abstract available.
9.
Tamiya M, Fujikawa K, Suzuki H, Yokoyama T, Uenami T, Tamiya A, et al.
Invest New Drugs
. 2022 Jan;
40(2):361-369.
PMID: 35088212
Background And Objective: Osimertinib as first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor (EGFR) mutations remains controversial. Sequential EGFR-tyrosine kinase inhibitor (TKI) might be...
10.
Matsuo K, Tanaka S, Sakata M, Takeda H, Nagata A, Mori M, et al.
Case Rep Otolaryngol
. 2021 Oct;
2021:7500273.
PMID: 34691798
Primary nasopharyngeal mycobacteriosis is a rare disease. We present a case in which skull base bone erosion appeared and was alleviated during the course of the treatment. Bone complications occur...